Avenda Health, a California-based AI healthcare company creating the future of personalised prostate cancer care, has raised $10M in Series B funding led by VCapital. The round also includes Plug & Play Ventures and Wealthing VC Club participation.
Avenda Health will use the funds to accelerate the use of iQuest, an AI-enabled patient management software that identifies and visualises a patient’s prostate cancer. Further, the funding will also be used to continue clinical evidence development.
Personalised prostate cancer care
Founded by Shyam Natarajan, Brit Berry-Pusey, and Leonard S. Marks, Avenda Health is creating a more personalised future for prostate cancer care.
Using deep learning, Avenda Health software maps a patient’s cancer in 3D, giving physicians precise information and the confidence to make care decisions.
The company aims to improve outcomes, preserve the quality of life, and create a new standard of cancer care.
The company’s FocalPoint System powered by iQuest reimagines laser ablation with a system to treat prostate cancer in-office under ultrasound guidance while preserving the quality of life.
The system spares healthy tissue by targeting only the tumor, minimises side effects, and uses patient-specific information and AI to deliver a precise and personalised treatment.
“Our company’s mission is to provide clinicians and their patients greater access to care while maintaining the quality of life often missing in prostate cancer treatment. Our technology is solving key issues in men’s health, and we look forward to creating real change in prostate cancer care,” says Dr. Shyam Natarajan, co-founder, and CEO of Avenda Health. “This funding will play a critical role in expanding the capability and reach of our technology while adding to our experienced team of Urology, medical device, and AI leaders.”
At the 2022 American Urological Association annual meeting, the company claimed that a retrospective study of 50 patients showed iQuest improved tumor encapsulation1 over conventional treatment planning from 56% to 80%.
“We are thrilled to be a part of Avenda Health’s journey in making incredible strides in the future of prostate cancer care, ” says Ryan Kole, Partner at VCapital. “Investing in something meaningful, innovative, and groundbreaking in men’s health is something VCapital is proud of.”
